


Healthcare News Roundup: Generic Pharmaceuticals
HSMN NewsFeed - 29 Sep 2016
Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
HSMN NewsFeed - 20 Sep 2016
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
